MILLBURN, N.J., Feb. 17 /PRNewswire/ -- Dr. Arthur L. Caplan, PhD will be the keynote speaker at Defined Health and Communitech's fifth annual Therapeutic Insight Conference. Therapeutic Insight 2005 ("TI2005") will take place on May 1 - 3, 2005, at the Ritz-Carlton, Boston.
Dr. Caplan is Emmanuel and Robert Hart Professor of Bioethics, Center for Bioethics & Department of Medical Ethics, University of Pennsylvania. He is chair of the Department of Medical Ethics at University of Pennsylvania, in addition to serving as the Trustee Professor and Director of the University's Center for Bioethics. Dr. Caplan is also a Professor in the Department of Philosophy and in the Department of Psychiatry in the School of Medicine. He is the author or editor of more than twenty books and over 500 papers in refereed journals, has written a weekly newspaper column on bioethics for the Hearst/King Features syndicate and currently writes a regular column on bioethics for MSNBC.com.
Dr. Caplan's keynote presentation at Therapeutic Insight 2005 is entitled, "Drug Safety, Blockbusters, Omics and Ethics: Implications for Drug Development and Commercialization." Drug safety is a key issue for the industry, its regulators and the public. Defined Health has asked Dr. Caplan to explore the implications of commercial blockbusters in the context of current clinical trial standards, shareholder expectations and the increasingly realizable potential of pharmacogenomics, physiomics and metabolomics. In the spirit of previous Therapeutic Insight keynote presentations, Dr. Caplan's observations are expected to lead to a provocative and constructive dialogue around this important issue.
In addition to Dr. Caplan, speakers at Therapeutic Insight 2005 are: Karen Bernstein, PhD, Chairman and Editor-in-Chief, BioCentury Publications Michael D. Clayman, MD, Vice President, Lilly Research Laboratories, Eli Lilly Howard Fillit, MD, Executive Director, The Institute for the Study of Aging Frederick Frank, Vice Chairman and Director, Lehman Brothers James A. Geraghty, Senior Vice President, Cardiovascular Division, Genzyme Thomas D. Giles, MD, Professor of Medicine and Director of Cardiovascular Research, Louisiana State University Medical School, Department of Medicine, Cardiovascular Research Laboratory Robert H. Glassman, MD, Director, Healthcare Investment Banking, M & A Group, Merrill Lynch Mitchell H. Gold, MD, President & Chief Executive Officer, Dendreon George S. Golumbeski, PhD, Vice President Business Development Licensing & Strategy - Oncology, Novartis Pharmaceuticals Corp. Thomas Hofstaetter, PhD, Senior Vice President Corporate Business Development, Wyeth Pharmaceuticals Tamar D. Howson, Senior Vice President, Corporate & Business Development, Bristol-Myers Squibb Company Steven M. Kelsey, MD, FRCP, FRCPath Group Director, Genentech BioOncology Arthur M. Krieg, MD, Chief Scientific Officer, Coley Pharmaceutical Group Jonathan S. Leff, Managing Director, Warburg Pincus Jeremy Levin, PhD, Global Head, Strategic Alliances, Novartis Institutes Biomedical Research Clive A. Meanwell, MD, Chairman & CEO, The Medicines Company Arlene Morris, President & CEO, Affymax Paul Nakagaki, PhD, Head of Pharma Research Strategy, Roche Aileen Nicoletti, PhD, Senior Consultant, Defined Health Elizabeth Ofili, MD, MPH, FACC, Professor of Medicine, Chief of Cardiology, and Director, Clinical Research Center, Morehouse School of Medicine Menelas Pangalos, PhD, VP Neurosciences Drug Discovery, Wyeth Rodney Pearlman, PhD, Co-Founder, President and CEO, Saegis Pharmaceuticals Paul M. Ridker, MD, MPH, Eugene Braunwald Professor of Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School Neal Rosen, MD, PhD, Professor of Medicine, Memorial Sloan Kettering Cancer Center Edward C. Saltzman, President, Defined Health Bruce J. Seeley, Sr. Director Commercial Development & Business Unit Operations, Genentech BioOncology Thomas Sheehan, Managing Director, Morgan Stanley
Therapeutic Insight 2005 is sponsored by Defined Health, Communitech Market Intelligence and Goodwin Procter LLP. To register, or for more information, please visit http://www.therapeuticinsight.com/, or contact Communitech (914) 245-7764, http://www.cmius.com/, or Defined Health (973) 921- 2850, http://www.definedhealth.com/.
About Defined Health
Founded more than 20 years ago, Defined Health (http://www.definedhealth.com/) is a leading biopharmaceutical business development strategy consulting firm whose clients include a mix of pharma, emerging and specialty pharma, biotech, and healthcare investment companies. Defined Health's consultants hold advanced degrees in science, medicine and business, and have industry experience in business development, commercial evaluation, finance, licensing, drug discovery and R&D. Defined Health's clients include more than half of the world's top 20 pharmaceutical companies.
Contact: Ginny E. Llobell Vice President Defined Health 973-921-2850
Defined HealthCONTACT: Ginny E. Llobell, Vice President, Defined Health,+1-973-921-2850
